Baker Biotech Capital (GP), LLC Insider Trading $SGEN Seagen Inc.
Get free email notifications about insider trading for Baker Biotech Capital (GP), LLC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Baker Biotech Capital (GP), LLC. Baker Biotech Capital (GP), LLC is 10% Owner in BIOCRYST PHARMACEUTICALS INC ($BCRX) and Director in INCYTE CORP ($INCY) and Director in NEUROGEN CORP ($NRGN) and 10% Owner in IDERA PHARMACEUTICALS, INC. ($IDRA) and 10% Owner in PHARMACYCLICS INC ($PCYC) and 10% Owner in VIROPHARMA INC ($VPHM) and 10% Owner in ADOLOR CORP ($ADLR) and 10% Owner in ALLOS THERAPEUTICS INC ($ALTH) and 10% Owner in Ardea Biosciences, Inc./DE ($IBPI) and Director in SEATTLE GENETICS INC /WA ($SGEN) and Director in GENOMIC HEALTH INC ($GHDX) and 10% Owner in AUXILIUM PHARMACEUTICALS INC ($AUXL).
Baker Biotech Capital (GP), LLC in Seagen Inc.
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of Baker Biotech Capital (GP), LLC: Director
Holdings: 4,626,213 shares
Current Value: $281,227,488
Latest Transaction: May 04 2010
$SGEN Market Capitalization: $8.71B
$SGEN Previous Close: $60.79
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of Baker Biotech Capital (GP), LLC in Seagen Inc.
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ADLR, ALTH, IBPI, AUXL, BCRX, GHDX, IDRA, INCY, NRGN, PCYC, SGEN, VPHM
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 04 2010 | SGEN | SEATTLE GENETICS I ... | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 10.75 | 273,404 | 2,939,093 | 4,626,213 | 4.4 M to 4.6 M (+6.28 %) |
| May 20 2009 | SGEN | SEATTLE GENETICS I ... | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 9.72 | 378,053 | 3,674,675 | 4,352,809 | 4 M to 4.4 M (+9.51 %) |
| Mar 19 2008 | SGEN | SEATTLE GENETICS I ... | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 8.02 | 17,793 | 142,732 | 3,974,756 | 4 M to 4 M (+0.45 %) |
| Mar 19 2008 | SGEN | SEATTLE GENETICS I ... | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 7.80 | 23,873 | 186,231 | 3,956,963 | 3.9 M to 4 M (+0.61 %) |
| Mar 14 2008 | SGEN | SEATTLE GENETICS I ... | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 8.06 | 14,740 | 118,738 | 3,933,090 | 3.9 M to 3.9 M (+0.38 %) |
| Mar 14 2008 | SGEN | SEATTLE GENETICS I ... | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 8.08 | 31,566 | 255,161 | 3,918,350 | 3.9 M to 3.9 M (+0.81 %) |
| Mar 14 2008 | SGEN | SEATTLE GENETICS I ... | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 7.93 | 14,396 | 114,090 | 3,886,784 | 3.9 M to 3.9 M (+0.37 %) |
| Mar 14 2008 | SGEN | SEATTLE GENETICS I ... | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 7.98 | 4,302 | 34,337 | 3,872,388 | 3.9 M to 3.9 M (+0.11 %) |
| Feb 11 2008 | SGEN | SEATTLE GENETICS I ... | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 9.06 | 8,601 | 77,885 | 3,868,086 | 3.9 M to 3.9 M (+0.22 %) |
| Feb 11 2008 | SGEN | SEATTLE GENETICS I ... | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 8.94 | 346 | 3,093 | 3,859,485 | 3.9 M to 3.9 M (+0.01 %) |
| Feb 11 2008 | SGEN | SEATTLE GENETICS I ... | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 9.00 | 19,896 | 179,112 | 3,859,139 | 3.8 M to 3.9 M (+0.52 %) |
| Feb 11 2008 | SGEN | SEATTLE GENETICS I ... | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 9.00 | 5,810 | 52,287 | 3,839,243 | 3.8 M to 3.8 M (+0.15 %) |
| Jan 23 2008 | SGEN | SEATTLE GENETICS I ... | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 8.78 | 18,869 | 165,623 | 3,833,433 | 3.8 M to 3.8 M (+0.49 %) |
| Jan 23 2008 | SGEN | SEATTLE GENETICS I ... | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 9.00 | 560,047 | 5,040,423 | 3,814,564 | 3.3 M to 3.8 M (+17.21 %) |
| Jul 11 2007 | SGEN | SEATTLE GENETICS I ... | Baker Biotech Capital (GP), LL ... | Director | Option Exercise | C | 0.00 | 210,130 | 0 | 0 | |
| Jul 11 2007 | SGEN | SEATTLE GENETICS I ... | Baker Biotech Capital (GP), LL ... | Director | Buy | C | 0.00 | 2,101,300 | 0 | 3,254,517 | 1.2 M to 3.3 M (+182.21 %) |
| Feb 16 2007 | SGEN | SEATTLE GENETICS I ... | Baker Biotech Capital (GP), LL ... | Director | Option Exercise | C | 0.00 | 61,700 | 0 | 210,130 | |
| Feb 16 2007 | SGEN | SEATTLE GENETICS I ... | Baker Biotech Capital (GP), LL ... | Director | Sell | S | 8.72 | 999,782 | 8,718,099 | 1,153,217 | 2.2 M to 1.2 M (-46.44 %) |
| Feb 16 2007 | SGEN | SEATTLE GENETICS I ... | Baker Biotech Capital (GP), LL ... | Director | Buy | C | 0.00 | 617,000 | 0 | 2,152,999 | 1.5 M to 2.2 M (+40.17 %) |
Page: 1